Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
Coopering	no tor tome recor to			Application Number	10/593133	
	ORMATION			Filing Date	09/18/2006	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Douglas Critcher	
	(Use as many she	ate as n	acatean)	Art Unit	1614	
(ood to many anothe to necessary)				Examiner Name	not yet assigned	
Sheet	9	of	10	Attorney Docket Number	PC25930 US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	57	Chemical Abstracts Service, Columbus OH, USA; xp002330925, retrieved from STN, Accession No. 1969;36415, rn 23142-47-4	:
	58	Chemical abstracts service, Columbus, OH, USA xp002330926, retrieved from STN accession no. 1964:3141 rn 94711-31-6	
	59	Database crossfire beilstein institut zur foerderung der chemischen wissenschaften; xp002330927 Beilstein registry no. 316683	
	60	GUARNERI M et al. "Contributo alla conoscenza di pirazolsulfonamidi" Annali di Chimica, vol. 49, 1959, pages 958-963.	
	61	KOCH A et al. Quantitative Structure-Activity Relationships. vol. 12, no. 4, 1993 pp. 373-382.	
	62	ALBERTI C et al. Farmaco, Edizione Scientifica, vol. 21, no. 12, 1966, pp. 883-891.	
	63	ALBERTI C et al. Farmaco, Edizione Scientifica, vol. 19, no. 7, 1964, pp. 618-637.	
	64	ALBERTI C et al. Farmaco, Edizione Scientifica, vol. 17, no. 6, 1962, pp. 460-467.	
	65	ALBERTI C et al. Farmaco, Edizione Scientifica, vol. 29, no. 12, 1974 pp. 957-966.	
	66	ALBERTI C et al. Farmaco, Edizione Scientifica, vol. 26, no. 1, 1971, pp. 66-88.	

Examiner	Date	
Signature	Considered	-

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete If Known		
Gabana				Application Number	10/593133	
INF	DRMATION	DIS	CLOSURE	Filing Date	09/18/2006	
STA	STATEMENT BY APPLICANT			First Named Inventor	Douglas Critcher	
(Use as many sheets as necessary)				Art Unit	1614	
				Examiner Name	not yet assigned	
Sheet	10	of	10	Attorney Docket Number	PC25930A US	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*			T ²		
	67	FUSCO, R et al. Farmaco, Edizione Scientifica, vol. 23, no. 19, 1968 pp. 919-944.			
1			4		

Examiner	Date	·
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.